Prollenium Adds RENEW™+ Skin Booster to the REVANESSE® Collection
Article content
The product marks a new era for dermal injections with long-lasting hydration to improve skin quality from the inside out.
Article content
Article content
RICHMOND HILL, Ontario — Prollenium, a global leader in medical aesthetic technology, launches Renew™+ to the Revanesse ® family of dermal fillers in Canada. Available immediately, Revanesse® Renew™+ is a unique skin booster that combines low and high molecular weight hyaluronic acid (HA) to hydrate and rejuvenate the skin below the surface, improving skin texture and creating a smoother, more radiant appearance.
Article content
Unlike traditional fillers, Revanesse® Renew™+ is a skin-boosting injection made with 100% high-purity, non-cross-linked HA with a low viscosity and easy spreadability. It is ideal for improving skin quality. Injected into the top layers of skin on the face, neck, or chest, it attracts and retains water molecules, adding an extra moisture boost for a refreshed and renewed look.
Article content
'Renew™+ is a first-of-its-kind dermal filler made in Canada and continues the tradition of breakthrough innovations for the family of Revanesse® products,' said Tim Lee, Chief Scientific Officer of Prollenium. Revanesse® Renew™+ marks the next generation of dermal injections, using the latest technology and advancements to create a lasting solution that leaves patients glowing and rejuvenated.
Article content
The Revanesse® family of dermal fillers features multi-purpose HA-based dermal fillers that provide real results instantly with a quick, minimally invasive beauty treatment. Revanesse® Renew+™ penetrates deeply to hydrate from within, reducing the appearance of fine lines and wrinkles for smoother, plumper skin. Works on the skin's surface to firm, tone, and lock in moisture for a more lifted, youthful look.
Article content
'At Prollenium, we're committed to creating top-of-the-line products to help health care providers give patients the refreshed look they've always wanted,' said Walter Geiger, acting CEO of Prollenium. 'This latest product in the Revanesse® line underscores our dedication to equipping providers with the latest technology and advancements in the medical aesthetics industry.'
Article content
Revanesse® Renew™+ is administered via microinjections into the superficial dermis using fine gauge needles, spaced evenly, 1 cm apart across the desired treatment area. For optimal results, it is recommended to have 2 treatments at 4 weeks apart.
Article content
About Prollenium
Prollenium leads the way in facial aesthetics and rejuvenation technology, turning complex science into reliable, effective products. As the first FDA-approved dermal filler manufacturer in North America, Prollenium redefines standards with cutting-edge innovation, exceptional safety, and a portfolio tailored to patient needs.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 days ago
- Cision Canada
iGan Partners Leads Seed+ Financing for Cosm Medical to Advance Personalized Gynecological Devices
TORONTO, June 5, 2025 /CNW/ - iGan Partners is pleased to announce that it has led the first close of a Seed+ financing round for Cosm Medical, a medical device company modernizing pelvic health through personalized gynecological care. The round included new investor Spring Impact Capital and several angels, and will support Cosm's U.S. expansion, clinical validation, and commercial growth. Cosm's flagship platform, Gynethotics TM, combines medical imaging, AI-driven design software, and 3D printing to create custom vaginal devices – starting with pessaries – tailored to each patient's unique anatomy and needs. The solution addresses a widespread but underserved women's health issue: pelvic floor disorders, which affect up to half of all women in their lifetime. "Cosm is modernizing a long-overlooked space in women's health through a personalized, data-driven platform grounded in precision care," said Sam Ifergan, Founding Partner at iGan Partners. "We're excited to support their mission to improve outcomes and quality of life for millions of women." "At Cosm, we're not just building a product—we're redefining an entire category of women's health. Our Gynethotics™ platform is more than just technology; it's a commitment to precision, personalization, and dignity in care. With the support of iGan Partners and our investors, we're accelerating a future where women are no longer underserved – where every solution is tailored, and true innovation means changing lives. This is just the beginning." – Derek Sham, Founder & CEO of Cosm Medical. "We were impressed with Derek's experience in commercializing medical devices, as well as COSM's extraordinary team, depth of intellectual property and thoughtfulness of the go-to-market strategy, said Olivia Hornby, Managing Partner at Spring Impact Capital. "As impact investors, we were excited by COSM's mission of building customized and data centric Gynethotics solutions – providing better care for the huge percentage of women who suffer from pelvic floor disorders. Gynethotics TM pessaries are approved for sale in both Canada and the U.S., and Cosm is actively expanding its presence across North America. The company is also building its clinical dataset and advancing its product pipeline to support new applications beyond pessary support, including postpartum and post-surgical recovery. About Cosm Medical Cosm Medical is a medical device company developing a hardware and software platform to personalize the treatment of pelvic floor disorders (PFDs), such as incontinence and pelvic organ prolapse. Its first product, Gynethotics TM, is a made-to-measure gynecological prosthetics platform that combines imaging, AI, and 3D printing to improve pessary performance, enhance patient comfort, and reduce complications. Cosm is redefining care for a long-overlooked area of women's health through precision medicine and digital innovation. Learn more at About iGan Partners iGan Partners is a North American venture capital firm focused on investing in emerging leaders in medical technology and digital health. We partner with founders building transformative solutions to improve patient outcomes, reduce system inefficiencies, and enable the future of data-driven care. iGan provides capital and strategic support to early commercial-stage companies across MedTech, digital health, diagnostics, and health IT. Our team brings deep sector expertise, a strong cross-border network, and a track record of scaling healthcare ventures from early growth to successful exit. Learn more at
Cision Canada
2 days ago
- Cision Canada
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /CNW/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
Cision Canada
2 days ago
- Cision Canada
BTL Announces Expanded Clearances and Versatility for EMSELLA® Platform
TORONTO, June 5, 2025 /CNW/ -- BTL, a global leader in non-invasive medical solutions, proudly announces expanded Health Canada License for its revolutionary EMSELLA® platform, reinforcing its leadership in pelvic health and intimate wellness. FDA-cleared and Health Canada-licensed for the treatment of urinary incontinence in both men and women, Emsella now also holds an additional Health Canada license and CE-mark certification for enhancing sexual function in patients experiencing somatic sexual arousal disorders caused by weak pelvic floor muscles. Backed by robust clinical outcomes, EMSELLA continues to redefine non-invasive care across pelvic health and sexual function. Key findings include: Sexual Dysfunction Statistics: 76% improvement in sexual satisfaction and desire 1 60% improvement in orgasm quality 1 37% improvement in maintaining erection during intercourse 2 48% improvement in pelvic muscle endurance 3 When compared to other modalities, EMSELLA outperforms significantly: 7x more effective than pelvic floor muscle training "EMSELLA continues to surpass expectations—not just in treating incontinence but in restoring confidence, and overall quality of life," said David Chmel, CEO of BTL North America. "These expanded clearances and clinical outcomes validate what providers and patients have long experienced: EMSELLA delivers meaningful results in a way that's accessible, comfortable, and non-invasive." Shari Caplan, MD, CCFP, FCFP, FAARM, a board-certified expert in functional, integrative , anti-aging, and intimate health said, "We're witnessing a complete shift in how pelvic and sexual health is approached. Patients are achieving results we used to think were only possible with surgery or years of therapy. EMSELLA has become a go-to solution in my practice for urinary control and sexual wellness for both men and women." As the demand for intimate wellness treatments rises, EMSELLA remains uniquely positioned as an effective and versatile tool for addressing some of the most intimate and often under-discussed health concerns. To learn more about EMSELLA, visit About BTL Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 350+ patents and over 580 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes , EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others. For more information, visit
